Neuroprotective and remyelinating activity shown by Bionure's compounds open a new pathway research for diseases as MS
The ability of promoting neuroprotection and remyelination shown by Bionure’s compounds could offer new treatment options for other neurodegenerative diseases as for example Multiple Sclerosis (MS).
MS is a condition which can affect the brain, nerves and spinal cord, causing a wide range of potential symptoms, including problems with vision, arm or leg movement, sensation or balance.
As ophthalmological diseases like Optic Neuritis or Neuromyelitis Optica, MS is considered and immune-mediated disease in which patient’s immune system attacks Central Nervous System (CNS), destroying myelin and causing nerve inflammation. MS may develop at multiple sites throughout the CNS, thus producing a variety of neurological symptoms that will differ among people with MS in type and severity.
MS is significantly more common in women than men, by a ratio of as much as 3 to 1. MS is most commonly diagnosed in individuals between the ages of 20 and 40, although it can develop in young children, teens and older adults.
MS Standard of Care
MS cannot be cured yet. There are now approved medications that have been shown to "modify" the course of MS by reducing the number of relapses and delaying progression of disability to some degree. In addition, many therapeutic and technological advances are helping people manage symptoms.
Bionure’s lead compound BN201 has showed it can promote remyelination as well as neuroprotection, offering a new hope in the efforts to find an effective treatment for MS patients.
More than 2.3 million people are affected by MS worldwide. Because some countries do not require physicians to report new cases, and because symptoms can be completely invisible, the prevalence of MS can only be estimated.